Can I drink alcohol during treatment with ruxolitinib tablets (JAKAVI)?

Ruxolitinib tablets (JAKAVI) is a JAK (Januskinase) inhibitor, mainly used to treat diseases such as polycythemia vera and myelodysplastic syndrome. It modulates the immune system and reduces disease symptoms by inhibiting the JAK-STAT signaling pathway. However, whether you can drink alcohol during treatment with ruxolitinib tablets is a question that needs careful consideration. Possible interactions and risks between ruxolitinib tablets and alcohol consumption are discussed below.

1. Metabolism and liver function of ruxolitinib tablets

The metabolism of ruxolitinib tablets in the body is mainly carried out by the enzyme system in the liver, especially cytochrome P450 (CYP) enzyme. Drinking alcohol may have an impact on liver function. Especially in the case of long-term drinking or heavy drinking, the metabolic function of the liver may be damaged. Since the metabolism of ruxolitinib tablets depends on the liver, drinking alcohol during treatment may interfere with the metabolism of ruxolitinib tablets, causing fluctuations in drug concentration, thereby affecting the efficacy and side effects of the drug. In particular, heavy drinking may increase the burden on the liver, thereby aggravating the hepatotoxicity of the drug.

2. Interaction between ruxolitinib tablets and alcohol

Although ruxolitinib tablets have not been directly shown to have serious interactions with alcohol, drinking alcohol may worsen the adverse effects of the drug, especially in the liver. Ruxolitinib tablets themselves may cause liver function abnormalities, including adverse reactions such as elevated liver enzymes. If you drink alcohol during treatment, especially excessive drinking, it may increase the burden on the liver and increase the risk of liver damage. Therefore, doctors generally recommend avoiding heavy alcohol consumption during ruxolitinib treatment, especially in patients with pre-existing liver disease or poor liver function.

3. The impact of ruxolitinib tablets on the immune system

Ruxolitinib tablets, as an immunomodulatory drug, will suppress certain immune responses, which may lead to an increased risk of infection. Alcohol intake, especially excessive drinking, can also have a negative impact on the immune system, weakening immune function and increasing the risk of infection. The immunosuppressive effects associated with ruxolitinib treatment and the immunosuppressive effects of alcohol may be additive, making patients more susceptible to infection or other complications. Therefore, to avoid problems such as infection, alcohol consumption during treatment should be limited as much as possible.

Overall, although there are no direct contraindications for ruxolitinib tablets and alcohol, considering the metabolism of the drug, potential effects on the liver, and immune system regulation, it is recommended to avoid drinking alcohol, especially excessive drinking, during treatment with ruxolitinib tablets. If the patient has a drinking habit, it is best to discuss the safe range of drinking with a doctor and regularly monitor liver function and immune status. Properly controlling the amount of alcohol you drink can help maximize the effectiveness of treatment and reduce potential health risks.

Reference materials:https://www.jakavi.com/